May 12, 2022
May 10, 2022
May 13, 2022
Mitsubishi Tanabe Pharma Corporation (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved Radicava ORS (edaravone), the oral form of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that currently has no cure […]
May 4, 2022
Swiss biotechs saw record-breaking revenue and R&D investment in 2021, which the industry hopes will lead people to look beyond homegrown giants like Roche and Novartis. The new findings, outlined by the Swiss Biotech Association in its latest annual report […]
April 25, 2022
At the same time that the implications of the global pandemic have created difficulties for many, they have also sparked an opportunity for growth and change. One key area that has continued to evolve even as we return to a […]
May 10, 2022
Contract PharmaPfizer and Biohaven Pharmaceuticals have entered into an agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults. Pfizer will pay approximately […]
May 10, 2022
Biopharma DiveOver the past few years, the Food and Drug Administration has come increasingly under scrutiny for its program to grant speedy approvals to drugs that show early signs of benefiting patients with life-threatening diseases. These so-called accelerated approvals have ushered […]
Cell and Gene Therapy, Industry
May 9, 2022
FierceBiotechThe sun and shares are rising again at LogicBio after the FDA lifted a clinical hold on a genome editing therapy for children with a rare disorder. Shares of the Lexington, Massachusetts-based biotech were sent skyward by 60% as the […]
Cell and Gene Therapy, Industry
May 9, 2022
FierceBiotechAspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company’s series B with $147.5 million following an initial $70 million round two years ago. The private neurodegenerative disease […]
May 9, 2022
Contract PharmaALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates […]
April 21, 2022
April 20, 2022
May 12, 2022
April 28, 2022
Copyright © 2022. All rights reserved
